サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1401386

消化器系治療薬の世界市場規模調査＆予測、薬剤クラス別、用途別、流通チャネル別、地域別分析、2023-2030年

Global Gastrointestinal Therapeutics Market Size Study & Forecast, by Drug Class, by Application, by Distribution Channel and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
消化器系治療薬の世界市場規模調査＆予測、薬剤クラス別、用途別、流通チャネル別、地域別分析、2023-2030年
出版日: 2023年11月15日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の消化器系治療薬市場は、2022年に約395億米ドルと評価され、予測期間2023～2030年には5％以上の健全な成長率で成長すると予測されています。

消化器系治療薬は、消化管に影響を及ぼす障害の特定と管理を目的とする医学の特定分野です。主に、胃、小腸、大腸、直腸などの消化器系臓器に影響を及ぼす問題の治療に取り組んでいます。症状を緩和し、胃腸系の全体的な機能を改善し、これらの症状に罹患している人々の生活の質を高めることを目的とした、薬物療法を含む様々な介入が含まれます。これらの治療市場は、胃腸障害の発生率の増加、高齢者人口の増加、主要企業による新製品の発売といった要因によって牽引されています。しかし、バイオシミラーの承認に関する政府の厳しい規制や、2023～2030年の予測期間中に医薬品の特許が失効することが市場成長の妨げとなっています。

消化器系治療薬市場の成長は、胃食道逆流症（GERD）、過敏性腸症候群（IBS）、胃腸がんなどの胃腸疾患の有病率の急増によって促進されています。全米幹細胞財団が発表した記事によると、2023年には80種類以上の自己免疫疾患が世界人口の4％近くを罹患し、最も多いのは1型糖尿病、関節リウマチ、ループス、クローン病、多発性硬化症、強皮症、乾癬です。さらに、消化器疾患に罹患しやすい高齢者の増加により、消化器治療薬の需要が高まっています。米国国立生物工学情報センター（NCBI）が2023年に発表した論文によると、炎症性腸疾患（IBD）の負担は世界的に増加しており、特に高齢者層での有病率が増加していると報告されています。さらに、消化器疾患と利用可能な治療法に対する患者の意識の高まりが、診断率の上昇と治療薬需要の増加につながり、市場の成長に寄与しています。また、医薬品研究開発の進歩は、新薬、新規デリバリーシステム、標的療法の発見につながり、市場にチャンスをもたらしています。精密医療、生物製剤、個別化治療アプローチにより、さまざまな消化器疾患に対する治療選択肢が拡大しています。例えば、アッヴィ社は2023年6月、中等度から重度の活動性を有する潰瘍性大腸炎の成人患者を対象に、リサンキズマブ（SKYRIZI）が主要評価項目である52週目の臨床的寛解を達成し、主要評価項目である副次的評価項目も達成したことを示す、第3相維持療法試験COMMANDの良好なトップライン結果を発表しました。

消化器系治療薬の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。2022年には、北米が消化器系治療薬の支配的な市場となりました。確立されたヘルスケアインフラ、高い購買力、消化器系治療薬の採用増加も市場の成長に寄与しました。さらに、同地域の主要企業が新製品を上市し、製品承認を取得したことも、市場の成長をさらに後押ししています。アジア太平洋地域は、食生活の変化、都市化、ライフスタイルの変化、消化器疾患の有病率上昇につながる高齢化などの要因により、予測期間中に大きな成長が見込まれています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 消化器系治療薬の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 消化器系治療薬の世界市場力学

  • 消化器系治療薬市場の影響分析（2020年～2030年）
    • 市場促進要因
      • 消化器疾患の有病率の増加
      • 高齢人口の増加
      • 製品上市数の増加
    • 市場の課題
      • バイオシミラーの承認に向けた政府の厳しい規制
      • 医薬品の特許切れ
    • 市場機会
      • 研究開発活動の活発化
      • 新興市場における成長機会

第4章 世界の消化器系治療薬市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 消化器系治療薬の世界市場：薬剤クラス別

  • 市場スナップショット
  • 消化器系治療薬の世界市場：薬剤クラス別、実績 - ポテンシャル分析
  • 消化器系治療薬の世界市場：薬剤クラス別推定・予測、2020年～2030年
  • 消化器系治療薬市場、サブセグメント分析
    • 生物製剤
    • プロトンポンプ阻害薬
    • アミノサリチル酸塩
    • 制酸剤
    • 緩下剤
    • H2拮抗薬
    • その他

第6章 消化器系治療薬の世界市場：用途別

  • 市場スナップショット
  • 消化器系治療薬の世界市場：用途別、実績 - ポテンシャル分析
  • 消化器系治療薬の世界市場：用途別推定・予測、2020年～2030年
  • 消化器系治療薬市場、サブセグメント分析
    • 炎症性腸疾患
    • 胃食道逆流症
    • 消化性潰瘍疾患
    • 過敏性腸症候群
    • その他

第7章 消化器系治療薬の世界市場：流通チャネル別

  • 市場スナップショット
  • 消化器系治療薬の世界市場：流通チャネル別、実績 - ポテンシャル分析
  • 消化器系治療薬の世界市場：流通チャネル別推定・予測、2020年～2030年
  • 消化器系治療薬市場、サブセグメント分析
    • 病院薬局
    • ドラッグストア
    • 小売薬局
    • オンラインプロバイダー

第8章 消化器系治療薬の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 消化器系治療薬市場、地域別市場スナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州消化器系治療薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋消化器系治療薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの消化器系治療薬市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Bristol-Myers Squibb Company
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • AbbVie Inc.
    • Pfizer Inc.
    • AstraZeneca plc
    • Bayer AG
    • Takeda Pharmaceutical Company Limited
    • Organon Group of Companies
    • Bausch Health Companies Inc.
    • Cosmo Pharmaceuticals N.V.
    • Teva Pharmaceutical Industries Limited

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Gastrointestinal Therapeutics Market, report scope
  • TABLE 2. Global Gastrointestinal Therapeutics Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Gastrointestinal Therapeutics Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
  • TABLE 4. Global Gastrointestinal Therapeutics Market estimates & forecasts by Application 2020-2030 (USD Billion)
  • TABLE 5. Global Gastrointestinal Therapeutics Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
  • TABLE 6. Global Gastrointestinal Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Gastrointestinal Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Gastrointestinal Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Gastrointestinal Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Gastrointestinal Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Gastrointestinal Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Gastrointestinal Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Gastrointestinal Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Gastrointestinal Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Gastrointestinal Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia Gastrointestinal Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA Gastrointestinal Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Gastrointestinal Therapeutics Market
  • TABLE 71. List of primary sources, used in the study of global Gastrointestinal Therapeutics Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Gastrointestinal Therapeutics Market, research methodology
  • FIG 2. Global Gastrointestinal Therapeutics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Gastrointestinal Therapeutics Market, key trends 2022
  • FIG 5. Global Gastrointestinal Therapeutics Market, growth prospects 2023-2030
  • FIG 6. Global Gastrointestinal Therapeutics Market, porters 5 force model
  • FIG 7. Global Gastrointestinal Therapeutics Market, pest analysis
  • FIG 8. Global Gastrointestinal Therapeutics Market, value chain analysis
  • FIG 9. Global Gastrointestinal Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Gastrointestinal Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Gastrointestinal Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Gastrointestinal Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Gastrointestinal Therapeutics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Gastrointestinal Therapeutics Market, regional snapshot 2020 & 2030
  • FIG 15. North America Gastrointestinal Therapeutics Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Gastrointestinal Therapeutics Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Gastrointestinal Therapeutics Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Gastrointestinal Therapeutics Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Gastrointestinal Therapeutics Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Gastrointestinal Therapeutics Market is valued at approximately USD 39.5 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 5% over the forecast period 2023-2030. Gastrointestinal therapeutics is a specific area of medicine that aims to identify and manage disorders that affect the gastrointestinal tract. It is primarily concerned with treating issues that affect the organs within the gastrointestinal system, such as the stomach, small intestine, large intestine, and rectum. It involves various interventions, including medications that aim to alleviate symptoms, improve the overall function of the gastrointestinal system, and enhance the quality of life for individuals affected by these conditions. The market for these treatments is driven by factors such as an increase in the incidence of gastrointestinal disorders, a growing geriatric population, and the launch of new products by key companies. However, the market growth is hindered by strict government regulations regarding the approval of biosimilars and the expiration of drug patents during the forecast period of 2023-2030.

The growth of the gastrointestinal therapeutics market is being fueled by a surge in the prevalence of gastrointestinal diseases such as Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome (IBS), and gastrointestinal cancers. According to an article published by the National Stem Cell Foundation, in 2023, over 80 different autoimmune diseases affect nearly 4% of the world population, with the most common being type 1 diabetes, rheumatoid arthritis, lupus, Crohn's disease, multiple sclerosis , scleroderma, and psoriasis. Additionally, the increase in elderly individuals who are more susceptible to gastrointestinal conditions has led to a rise in demand for gastrointestinal therapeutics. According to an article published by the National Center for Biotechnology and Information (NCBI) in 2023, which reported that the burden of inflammatory bowel disease (IBD) is increasing worldwide, with a particular increase in prevalence in the elderly population. Furthermore, patients increased awareness of gastrointestinal disorders and available treatments has led to higher diagnosis rates and increased demand for therapeutics, contributing to market growth. Advances in pharmaceutical research and development have also led to the discovery of new drugs, novel delivery systems, and targeted therapies, providing opportunities for the market. Precision medicine, biologics, and personalized treatment approaches are expanding the treatment options available for various gastrointestinal conditions. For example, in June 2023, AbbVie Inc. announced positive top-line results from its Phase 3 maintenance study, COMMAND, showing Risankizumab (SKYRIZI) achieved the primary endpoint of clinical remission at week 52, as well as key secondary endpoints in adult patients with moderately to severely active ulcerative colitis.

The key regions considered for the Global Gastrointestinal Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. In 2022, North America was the dominant market for gastrointestinal therapeutics due to the presence of several major players in the region. The well-established healthcare infrastructure, high purchasing power, and increased adoption of gastrointestinal therapeutics also contributed to the market's growth. Additionally, key players in the region launched new products and obtained product approvals, further boosting market growth. Asia Pacific is expected to experience significant growth over the forecast period due to factors such as changing dietary habits, urbanization, lifestyle shifts, and an aging population leading to a rise in the prevalence of gastrointestinal disorders.

Major market player included in this report are:

  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Pfizer Inc.
  • AstraZeneca plc
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Organon Group of Companies
  • Bausch Health Companies Inc.
  • Cosmo Pharmaceuticals N.V.
  • Teva Pharmaceutical Industries Limited

Recent Developments in the Market:

  • In May 2023, AbbVie announced that RINVOQ has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderately to severely active Crohn's disease who have not responded well to one or more TNF blockers, or cannot tolerate them. Additionally, in April 2023, AbbVie reported that RINVOQ has also been approved by the European Commission (EC) as the first oral Janus Kinase (JAK) inhibitor to treat adult patients with moderately to severely active Crohn's disease.
  • In May 2021, Bristol Myers Squibb made an announcement that the U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) 0.92 mg to treat adults with moderately to severely active ulcerative colitis (UC), which is a chronic Inflammatory Bowel Disease (IBD).
  • In January 2021, AstraZeneca, and Daiichi Sankyo Company, Limited announced the U.S. approval for Enhertu to treat HER2-positive Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma in adults who have received a previous trastuzumab-based regimen.

Global Gastrointestinal Therapeutics Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Drug Class, Application, Distribution Channel, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

  • Biologics
  • Proton Pump Inhibitors
  • Aminosalicylates
  • Antacids
  • Laxatives
  • H2 Antagonists
  • Others

By Application:

  • Inflammatory Bowel Disease
  • Gastroesophageal Reflux Disease
  • Peptic Ulcer Disease
  • Irritable Bowel Syndrome
  • Others

By Distribution Channel:

  • Hospitals Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Providers

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Gastrointestinal Therapeutics Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Gastrointestinal Therapeutics Market, by Drug Class, 2020-2030 (USD Billion)
    • 1.2.3. Gastrointestinal Therapeutics Market, by Application, 2020-2030 (USD Billion)
    • 1.2.4. Gastrointestinal Therapeutics Market, by Distribution Channel, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Gastrointestinal Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Gastrointestinal Therapeutics Market Dynamics

  • 3.1. Gastrointestinal Therapeutics Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increase in prevalence of gastrointestinal diseases
      • 3.1.1.2. Rise in geriatric population
      • 3.1.1.3. Rise in the number of product launches
    • 3.1.2. Market Challenges
      • 3.1.2.1. Stringent government regulations toward approval of biosimilars
      • 3.1.2.2. Expiration of the drugs patent
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rise in Research & Development activities
      • 3.1.3.2. Growth opportunities in emerging markets

Chapter 4. Global Gastrointestinal Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Gastrointestinal Therapeutics Market, by Drug Class

  • 5.1. Market Snapshot
  • 5.2. Global Gastrointestinal Therapeutics Market by Drug Class, Performance - Potential Analysis
  • 5.3. Global Gastrointestinal Therapeutics Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
  • 5.4. Gastrointestinal Therapeutics Market, Sub Segment Analysis
    • 5.4.1. Biologics
    • 5.4.2. Proton Pump Inhibitors
    • 5.4.3. Aminosalicylates
    • 5.4.4. Antacids
    • 5.4.5. Laxatives
    • 5.4.6. H2 Antagonists
    • 5.4.7. Others

Chapter 6. Global Gastrointestinal Therapeutics Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Gastrointestinal Therapeutics Market by Application, Performance - Potential Analysis
  • 6.3. Global Gastrointestinal Therapeutics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 6.4. Gastrointestinal Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Inflammatory Bowel Disease
    • 6.4.2. Gastroesophageal Reflux Disease
    • 6.4.3. Peptic Ulcer Disease
    • 6.4.4. Irritable Bowel Syndrome
    • 6.4.5. Others

Chapter 7. Global Gastrointestinal Therapeutics Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Gastrointestinal Therapeutics Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Gastrointestinal Therapeutics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
  • 7.4. Gastrointestinal Therapeutics Market, Sub Segment Analysis
    • 7.4.1. Hospitals Pharmacies
    • 7.4.2. Drug Stores
    • 7.4.3. Retail Pharmacies
    • 7.4.4. Online Providers

Chapter 8. Global Gastrointestinal Therapeutics Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Gastrointestinal Therapeutics Market, Regional Market Snapshot
  • 8.4. North America Gastrointestinal Therapeutics Market
    • 8.4.1. U.S. Gastrointestinal Therapeutics Market
      • 8.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Gastrointestinal Therapeutics Market
  • 8.5. Europe Gastrointestinal Therapeutics Market Snapshot
    • 8.5.1. U.K. Gastrointestinal Therapeutics Market
    • 8.5.2. Germany Gastrointestinal Therapeutics Market
    • 8.5.3. France Gastrointestinal Therapeutics Market
    • 8.5.4. Spain Gastrointestinal Therapeutics Market
    • 8.5.5. Italy Gastrointestinal Therapeutics Market
    • 8.5.6. Rest of Europe Gastrointestinal Therapeutics Market
  • 8.6. Asia-Pacific Gastrointestinal Therapeutics Market Snapshot
    • 8.6.1. China Gastrointestinal Therapeutics Market
    • 8.6.2. India Gastrointestinal Therapeutics Market
    • 8.6.3. Japan Gastrointestinal Therapeutics Market
    • 8.6.4. Australia Gastrointestinal Therapeutics Market
    • 8.6.5. South Korea Gastrointestinal Therapeutics Market
    • 8.6.6. Rest of Asia Pacific Gastrointestinal Therapeutics Market
  • 8.7. Latin America Gastrointestinal Therapeutics Market Snapshot
    • 8.7.1. Brazil Gastrointestinal Therapeutics Market
    • 8.7.2. Mexico Gastrointestinal Therapeutics Market
  • 8.8. Middle East & Africa Gastrointestinal Therapeutics Market
    • 8.8.1. Saudi Arabia Gastrointestinal Therapeutics Market
    • 8.8.2. South Africa Gastrointestinal Therapeutics Market
    • 8.8.3. Rest of Middle East & Africa Gastrointestinal Therapeutics Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Bristol-Myers Squibb Company
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. AbbVie Inc.
    • 9.3.3. Pfizer Inc.
    • 9.3.4. AstraZeneca plc
    • 9.3.5. Bayer AG
    • 9.3.6. Takeda Pharmaceutical Company Limited
    • 9.3.7. Organon Group of Companies
    • 9.3.8. Bausch Health Companies Inc.
    • 9.3.9. Cosmo Pharmaceuticals N.V.
    • 9.3.10. Teva Pharmaceutical Industries Limited

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption